NDA 020310 · Kramer
Nizoral Anti-Dandruff
Ketoconazole · Topical · Azole Antifungal
Last checked: Nov 20, 2026Latest source record: Apr 30, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1997
Oct 10, 1997
Approved uses
1
Original approval plus efficacy supplements
Registered trials
211
26 Phase 3, 4 recruiting
FAERS reports
17,634
9,513 serious, 1,123 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 20, 2026.
Uses controls flaking, scaling and itching associated with dandruff
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 10, 1997 Original approval · Type 3 - New Dosage Form ReviewOther Important Information from FDA
1 products under this application
- NIZORAL ANTI-DANDRUFF · KETOCONAZOLE 1% · SHAMPOO, TOPICAL · Over-the-counter
Clinical trials
Interventional ClinicalTrials.gov studies with "Ketoconazole" as an intervention, any sponsor and status, largest first.
- Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate EpisodesPivotal-lookingTerminated
Atrial Fibrillation NetworkAcademic, hospital or other
NCT02618577 · 2,608 participants · Start Feb 2016 · Primary completion Dec 31, 2022
Drug: Edoxaban; ASA · For: Atrial High Rate Episodes
Sites: Multiple Locations, Austria; Multiple Locations, Belgium; Multiple Locations, Bulgaria · 18 sites in all
- Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and RehabilitationPivotal-lookingTerminated
The University of Texas Medical Branch, GalvestonAcademic, hospital or other
NCT00675714 · 1,126 participants · Start Jan 2004 · Primary completion Sep 2018
Drug: Humatrope; Ketoconazole and 5 more · For: Burns
Sites: Galveston, Texas
- A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal MetastasesPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT00699751 · 921 participants · Start Jun 12, 2008 · Primary completion Jul 15, 2011
Drug: Radium-223 dichloride (Xofigo, BAY88-8223); Placebo and 1 more · For: Hormone Refractory Prostate Cancer; Bone Metastases
Sites: Los Angeles, California; Roseville, California; Tampa, Florida · 134 sites in all
- Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea PedisPivotal-lookingCompleted
Encube Ethicals Pvt. Ltd.Industry
NCT03824912 · 831 participants · Start Aug 23, 2018 · Primary completion Jan 24, 2019
Drug: Ketoconazole Cream 2%; Ketoconazole Cream 2% (G&W Laboratories Inc.) and 1 more · For: Tinea Pedis
Sites: Long Beach, California; Miami, Florida; Miami Lakes, Florida · 9 sites in all
- Anticoagulation in ICH Survivors for Stroke Prevention and RecoveryPivotal-lookingRecruiting
Yale UniversityAcademic, hospital or other
NCT03907046 · 700 participants (planned) · Start Jan 28, 2020 · Primary completion Apr 2027
Drug: Apixaban; Aspirin · For: Intracerebral Hemorrhage; Atrial Fibrillation
Sites: Birmingham, Alabama; Mobile, Alabama; Chandler, Arizona · 187 sites in all
- A Therapeutic Equivalence Study of Ketoconazole Cream 2%Pivotal-lookingCompleted
Douglas Pharmaceuticals America LtdIndustry
NCT04203342 · 682 participants · Start Dec 11, 2019 · Primary completion May 28, 2020
Drug: Experimental: Ketoconazole 2% Cream (Douglas Pharmaceuticals America Ltd.); Active comparator: Ketoconazole 2% Cream (Teva Pharmaceuticals USA) and 1 more · For: Tinea Pedis
Sites: Brandon, Florida; Tampa, Florida; Belize City, Belize
National Cancer Institute (NCI)NIH
NCT00032825 · 674 participants · Start Mar 19, 2002
Drug: Ketaconazole; Docetaxel · For: Prostatic Neoplasms
Sites: Bethesda, Maryland
- An Efficacy Study of a New Formulation of Ketoconazole 2% Cream in Patients With Tinea Pedis, Commonly Known as Athlete's FootPivotal-lookingTerminated
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
NCT01110330 · 583 participants · Start Jul 2007 · Primary completion Oct 2008
Drug: Placebo cream; Ketoconazole 2% cream (formulation F012) (Nizoral) and 1 more · For: Tinea Pedis
Sites: Bydgoszcz, Poland; Lodz, Poland; Lublin, Poland · 11 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective1,779
- off label use1,268
- pruritus1,020
- fatigue1,005
- nausea897
- rash874
- diarrhoea838
- headache768
- pain753
- psoriasis663
- dyspnoea653
- dizziness632
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 121 |
| 2005 | 131 |
| 2006 | 139 |
| 2007 | 132 |
| 2008 | 137 |
| 2009 | 265 |
| 2010 | 171 |
| 2011 | 321 |
| 2012 | 389 |
| 2013 | 362 |
| 2014 | 324 |
| 2015 | 923 |
| 2016 | 913 |
| 2017 | 941 |
| 2018 | 1,195 |
| 2019 | 1,367 |
| 2020 | 1,276 |
| 2021 | 1,193 |
| 2022 | 1,206 |
| 2023 | 1,804 |
| 2024 | 1,385 |
| 2025 | 1,601 |
| 2026 | 1,338 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Topical ketoconazole for the treatment of androgenetic alopecia: A systematic review.
Fields JR, Vonu PM, Monir RL, et al. · Dermatol Ther 2020 · Systematic Review
- Topical ketoconazole: a systematic review of current dermatological applications and future developments.
Choi FD, Juhasz MLW, Atanaskova Mesinkovska N · J Dermatolog Treat 2019 · Systematic Review
- Perpetrator Characteristics of Azole Antifungal Drugs on Three Oral Factor Xa Inhibitors Administered as a Microdosed Cocktail.
Rohr BS, Foerster KI, Blank A, et al. · Clin Pharmacokinet 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Ketoconazole associated hepatotoxicity: a systematic review and meta- analysis.
Yan JY, Nie XL, Tao QM, et al. · Biomed Environ Sci 2013 · Meta-Analysis, Systematic Review
- Effect of axitinib on the QT interval in healthy volunteers.
Ruiz-Garcia A, Houk BE, Pithavala YK, et al. · Cancer Chemother Pharmacol 2015 · Clinical Trial, Phase I, Comparative Study
- Efficacy of ozonized sunflower oil in the treatment of tinea pedis.
Menéndez S, Falcón L, Simón DR, et al. · Mycoses 2002 · Clinical Trial, Clinical Trial, Phase III
Sponsor: Kramer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.